90 Participants Needed

Dexmedetomidine for Postoperative Cognitive Dysfunction

Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Sunnybrook Health Sciences Centre
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.

What data supports the effectiveness of the drug Dexmedetomidine for postoperative cognitive dysfunction?

Research shows that Dexmedetomidine can reduce the risk of postoperative cognitive dysfunction (POCD) and improve cognitive scores after surgery, especially in elderly patients. It helps by reducing inflammation in the brain, which is linked to POCD.12345

Is dexmedetomidine safe for use in humans?

Dexmedetomidine is generally considered safe and is widely used as a sedative in surgical procedures, but it can cause side effects like low blood pressure (hypotension) and slow heart rate (bradycardia). In rare cases, it has been associated with serious events like cardiac arrest, especially in patients with certain heart conditions.678910

How is the drug Dexmedetomidine unique for treating postoperative cognitive dysfunction?

Dexmedetomidine is unique because it acts on a2-adrenergic receptors in the brain, providing sedative and neuroprotective effects, which may help improve cognitive function after surgery. Unlike other treatments, it also helps maintain hemodynamic balance (stable blood pressure and heart rate) and has minimal impact on breathing.2591112

What is the purpose of this trial?

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Research Team

SC

Stephen Choi, MD,MSc,FRCPC

Principal Investigator

Sunnybrook Health Sciences Centre

SA

Sinziana Avramescu, MD,PhD,FRCPC

Principal Investigator

Sunnybrook Health Sciences Centre

Eligibility Criteria

This trial is for individuals aged 60 or older who are scheduled for open heart surgery (CABG or valve replacement) and will recover in the CVICU. They must not have severe pre-existing cognitive issues, a history of certain heart conditions, liver cirrhosis, very slow heartbeat, advanced kidney disease, or be unable to attend follow-up assessments.

Inclusion Criteria

I am scheduled for heart surgery that requires opening my chest, with recovery in the CVICU.
I am 60 years old or older.

Exclusion Criteria

I do not have allergies or conditions that prevent me from taking dexmedetomidine.
I can attend all required study visits and complete tests.
Lack of patient consent
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive dexmedetomidine or standard sedation protocols immediately post-surgery, with dexmedetomidine administered for up to 24 hours

1 day
In-hospital stay

In-hospital Monitoring

Participants are monitored for delirium, hemodynamic stability, and other complications from post-operative day 0 to 10

10 days
Daily assessments

Follow-up

Participants are monitored for POCD, depression, and mild cognitive impairment at 3, 6, and 12 months post-surgery

12 months
Assessments at 3, 6, and 12 months

Treatment Details

Interventions

  • Dexmedetomidine
Trial Overview The study is testing whether Dexmedetomidine (DEX), given during cardiac surgery, can prevent long-term memory and thinking problems that sometimes occur after such operations. The goal is to see if DEX improves recovery and reduces hospital stays and healthcare costs.
Participant Groups
2Treatment groups
Active Control
Group I: Standard of Care GroupActive Control1 Intervention
Standard sedation protocols will be followed at the discretion of the attending physician.
Group II: Dexmedetomidine Hydrochloride GroupActive Control1 Intervention
Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).

Dexmedetomidine is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
🇺🇸
Approved in United States as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
🇨🇦
Approved in Canada as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation
🇯🇵
Approved in Japan as Precedex for:
  • Sedation in intensive care settings
  • Procedural sedation

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials
693
Recruited
1,569,000+

Findings from Research

In elderly patients undergoing major surgery, continuous infusion of dexmedetomidine (DEX) at doses of 200 μg or 400 μg significantly reduced the incidence of postoperative delirium (POD) and early postoperative cognitive dysfunction (POCD) compared to lower doses.
DEX 400 μg was particularly effective in reducing early POCD in patients who had open surgery, and this treatment did not lead to increased sedation, pain intensity, or side effects, indicating its safety and efficacy.
The Effect and Optimal Dosage of Dexmedetomidine Plus Sufentanil for Postoperative Analgesia in Elderly Patients With Postoperative Delirium and Early Postoperative Cognitive Dysfunction: A Single-Center, Prospective, Randomized, Double-Blind, Controlled Trial.Zhao, W., Hu, Y., Chen, H., et al.[2022]
In a study of 83 pediatric patients undergoing inguinal hernia repair, intranasal administration of dexmedetomidine resulted in lower rates of emergence agitation (4.76%) compared to intravenous administration (21.95%), indicating a more favorable awakening experience.
Patients receiving intranasal dexmedetomidine also showed better cognitive, language, and motor scores three days post-surgery, with a significantly lower incidence of cognitive dysfunction (4.76% vs. 21.95% for IV), suggesting that this route of administration may enhance early cognitive recovery.
Effect of different routes of administration on early cognitive function following inguinal hernia repair.Huang, J., Deng, B., Shuai, J., et al.[2021]
Dexmedetomidine significantly reduces the incidence of postoperative cognitive dysfunction (POCD) in elderly adults after general anesthesia, with a relative risk of 0.59 based on 13 randomized controlled trials.
The use of dexmedetomidine also improves cognitive function as measured by the Mini-Mental State Examination (MMSE) score on the first postoperative day, indicating its potential benefits in enhancing recovery after surgery.
Effect of dexmedetomidine on postoperative cognitive dysfunction in elderly patients after general anaesthesia: A meta-analysis.Zhou, C., Zhu, Y., Liu, Z., et al.[2022]

References

Does Dexmedetomidine Ameliorate Postoperative Cognitive Dysfunction? A Brief Review of the Recent Literature. [2020]
The Effect and Optimal Dosage of Dexmedetomidine Plus Sufentanil for Postoperative Analgesia in Elderly Patients With Postoperative Delirium and Early Postoperative Cognitive Dysfunction: A Single-Center, Prospective, Randomized, Double-Blind, Controlled Trial. [2022]
Effect of different routes of administration on early cognitive function following inguinal hernia repair. [2021]
Effect of dexmedetomidine on postoperative cognitive dysfunction in elderly patients after general anaesthesia: A meta-analysis. [2022]
The effect of dexmedetomidine on the perioperative hemodynamics and postoperative cognitive function of elderly patients with hypertension: Study protocol for a randomized controlled trial. [2022]
Dexmedetomidine as an Analgesic Agent with Neuroprotective Properties: Experimental and Clinical Aspects. [2021]
Dexmedetomidine related cardiac arrest in a patient with permanent pacemaker; a cautionary tale. [2013]
Dexmedetomidine use in pediatric airway reconstruction. [2022]
Influence of dexmedetomidine on postoperative cognitive dysfunction in the elderly: A meta-analysis of randomized controlled trials. [2022]
Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Patients Undergoing Procedure-Type Sedation. [2020]
[Feasibility and Safety of Dexmedetomidine Sedation in Transarterial Embolization for Hepatocellular Carcinoma with Hepatitis C-Related Cirrhosis]. [2015]
12.United Statespubmed.ncbi.nlm.nih.gov
The Effect of Dexmedetomidine on Cognitive Function and Protein Expression of Aβ, p-Tau, and PSD95 after Extracorporeal Circulation Operation in Aged Rats. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security